文献速递食管胃疾病与幽门螺杆菌消化内镜消化道肿瘤与早癌

反流依赖与非反流策略筛查巴雷特食管的成本效果比较

Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究用马尔可夫模型模拟50岁人群,比较反流依赖(慢性GERD白人男性)与非反流(全种族男女,BE患病率1.6%或5%)场景下多种BE筛查策略与不筛查的成本效果。结果显示,吞咽式食管细胞采集装置联合生物标志物在所有场景下均具成本效果且为最优策略;呼气挥发性有机物ICER最高。微创非内镜检测或使非反流依赖的BE筛查具成本效果,但需研究参与率。

要点

  • 吞咽式食管细胞采集装置联合生物标志物在所有场景下具成本效果且为最优筛查策略。
  • 呼气挥发性有机物在所有场景下ICER最高,成本效果最差。
  • 非反流依赖场景下多数非镇静内镜BE筛查试验具成本效果。

核心结论

  • 微创非内镜检测可能使非反流依赖的BE筛查具成本效果。
  • 吞咽式食管细胞采集装置联合生物标志物在所有场景下均为最优筛查策略。

研究设计与样本

  • 马尔可夫模型模拟50岁人群,假设队列500000人随访40年,支付意愿阈值100000美元/QALY。
  • 设置三种场景:反流依赖(慢性GERD白人男性)、非反流依赖(全种族男女,BE患病率1.6%)、非反流依赖(BE患病率5%)。
  • 比较镇静内镜、经鼻内镜、吞咽式食管细胞采集装置联合生物标志物、呼气挥发性有机物筛查与不筛查。

主要发现

  • 非反流依赖场景下,多数非镇静内镜BE筛查试验具成本效果。
  • 吞咽式食管细胞采集装置联合生物标志物ICER<35000美元/QALY,在所有场景下为最优筛查试验。
  • 呼气挥发性有机物在所有场景下ICER最高。
  • 反流依赖场景下所有试验ICER<25000美元/QALY,所有非镇静内镜试验均优于不筛查。
  • ICER对BE患病率和检测成本敏感。

关键数值与推荐

  • 成本效果阈值:100000美元/QALY。
  • 吞咽式食管细胞采集装置联合生物标志物ICER<35000美元/QALY。
  • 反流依赖场景下所有试验ICER<25000美元/QALY。

临床怎么用

  • 在非反流依赖人群中,可考虑采用吞咽式食管细胞采集装置联合生物标志物进行BE筛查。
  • 选择BE筛查策略时需考虑BE患病率和检测成本对成本效果的影响。
  • 非反流依赖筛查策略的参与率尚需进一步研究。

局限性

  • 非反流依赖筛查策略的参与率尚未研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Minimally invasive tests for Barrett's esophagus (BE) detection have raised the prospect of broader nonreflux-based testing. Cost-effectiveness studies have largely studied men aged 50 years with chronic gastroesophageal reflux disease (GERD) symptoms. We evaluated the comparative cost effectiveness of BE screening tests in GERD-based and GERD-independent testing scenarios. METHODS: Markov modeling was performed in 3 scenarios in 50 years old individuals: (i) White men with chronic GERD (GERD-based); (ii) GERD-independent (all races, men and women), BE prevalence 1.6%; and (iii) GERD-independent, BE prevalence 5%. The simulation compared multiple screening strategies with no screening: sedated endoscopy (sEGD), transnasal endoscopy, swallowable esophageal cell collection devices with biomarkers, and exhaled volatile organic compounds. A hypothetical cohort of 500,000 individuals followed for 40 years using a willingness to pay threshold of $100,000 per quality-adjusted life year (QALY) was simulated. Incremental cost-effectiveness ratios (ICERs) comparing each strategy with no screening and comparing screening strategies with each other were calculated. RESULTS: In both GERD-independent scenarios, most non-sEGD BE screening tests were cost effective. Swallowable esophageal cell collection devices with biomarkers were cost effective (<$35,000/QALY) and were the optimal screening tests in all scenarios. Exhaled volatile organic compounds had the highest ICERs in all scenarios. ICERs were low (<$25,000/QALY) for all tests in the GERD-based scenario, and all non-sEGD tests dominated no screening. ICERs were sensitive to BE prevalence and test costs. DISCUSSION: Minimally invasive nonendoscopic tests may make GERD-independent BE screening cost effective. Participation rates for these strategies need to be studied.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Sami SS, Moriarty JP, Rosedahl JK, et al. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. Am J Gastroenterol. 2021. PMID: 34131096. doi:10.14309/ajg.0000000000001336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。